Adalimumab in psoriatic arthritis: 24-week results of a phase III study

被引：0
|
作者：
Mease, P
Gladman, D
Ritchlin, C
Weinberg, M
机构：
[1] Univ Washington, Sch Med, Seattle, WA USA
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ Rochester, Rochester, NY USA
[4] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2005年 / 52卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：P2 / P2
页数：1
相关论文
共 50 条
  • [31] Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol
    van der Heijde, D.
    Fleischmann, R.
    Wollenhaupt, J.
    Deodhar, A.
    Kielar, D.
    Woltering, F.
    Stach, C.
    Hoepken, B.
    Arledge, T.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 233 - 237
  • [32] Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study
    Reich, K.
    Pinter, A.
    Lacour, J. P.
    Ferrandiz, C.
    Micali, G.
    French, L. E.
    Lomaga, M.
    Dutronc, Y.
    Henneges, C.
    Wilhelm, S.
    Hartz, S.
    Paul, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (04) : 1014 - 1023
  • [33] Switching from infliximab or adalimumab to etanercept 50 mg/once weekly in resistant or intolerant patients with rheumatoid arthritis: 24-week results.
    Cantini, F
    Niccoli, L
    Porciello, G
    Storri, L
    Chindamo, D
    Nannini, C
    Benucci, M
    Salvarani, C
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S560 - S560
  • [34] EFFECT OF CERTOLIZUMAB PEGOL ON THE MULTIPLE FACETS OF PSORIATIC ARTHRITIS AS REPORTED BY PATIENTS: 24-WEEK PATIENT REPORTED OUTCOME RESULTS OF A PHASE 3 DOUBLE BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY
    Gladman, D.
    Fleischmann, R.
    Coteur, G.
    Woltering, F.
    Mease, P.
    VALUE IN HEALTH, 2013, 16 (03) : A227 - A227
  • [35] IMPACT OF GOLIMUMAB, AN ANTI-TNFA MONOCLONAL ANTIBODY, ON HEALTH RELATED QUALITY OF LIFE (HRQOL) AND WORK PRODUCTIVITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 24-WEEK RESULTS OF THE PHASE III GO VIBRANT TRIAL
    Husni, M.
    Kavanaugh, A.
    Peterson, S.
    Han, C.
    Chan, E.
    Hsia, E. C.
    Kim, L.
    Lo, K. H.
    Harrison, D. D.
    Li, N.
    VALUE IN HEALTH, 2017, 20 (09) : A538 - A538
  • [36] Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double- blind randomised placebo- controlled study (RAPID-PsA)
    Mease, P. J.
    Fleischmann, R.
    Deodhar, A. A.
    Wollenhaupt, J.
    Khraishi, M.
    Kielar, D.
    Woltering, F.
    Stach, C.
    Hoepken, B.
    Arledge, T.
    van der Heijde, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 48 - 55
  • [37] Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial
    Husni, M. Elaine
    Kavanaugh, Arthur
    Chan, Eric K. H.
    Peterson, Steven
    Li, Nan
    Hsia, Elizabeth C.
    Kim, Lilianne
    Lo, Kim Hung
    Harrison, Diane D.
    Han, Chenglong
    VALUE IN HEALTH, 2020, 23 (10) : 1286 - 1291
  • [38] EFFECT OF SECUKINUMAB ON SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS: RESULTS OF A 24-WEEK MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    McInnes, Iain
    Sieper, Joachim
    Braun, Juergen
    Emery, Paul
    van der Heijde, Desiree
    Isaacs, John
    Dahmen, Georg
    Wollenhaupt, Juergen
    Schulze-Koops, Hendrik
    Gsteiger, Sandro
    Bertolino, Arthur
    Hueber, Wolfgang
    Tak, Paul P.
    RHEUMATOLOGY, 2012, 51 : 90 - 91
  • [39] Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis
    Kavanaugh, Arthur
    Mease, Philip J.
    Gomez-Reino, Juan J.
    Adebajo, Adewale O.
    Wollenhaupt, Juergen
    Gladman, Dafna D.
    Hochfeld, Marla
    Teng, Lichen L.
    Schett, Georg
    Lespessailles, Eric
    Hall, Stephen
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (03) : 479 - 488
  • [40] Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis Fifty-Two-Week Phase III Randomized Study Results
    Weinblatt, Michael E.
    Baranauskaite, Asta
    Dokoupilova, Eva
    Zielinska, Agnieszka
    Jaworski, Janusz
    Racewicz, Artur
    Pileckyte, Margarita
    Jedrychowicz-Rosiak, Krystyna
    Baek, Inyoung
    Ghil, Jeehoon
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (06) : 832 - 840
12345